Wed, Aug 14, 8:38 PM (153 days ago)
On August 14, 2024, Ensysce Biosciences, Inc. reported its financial results for the fiscal quarter ending June 30, 2024. The announcement was made via a press release, which is referenced as Exhibit 99.1 in their Form 8-K filing with the SEC. The company, traded under the symbol ENSC on the Nasdaq, emphasized that the information provided is not to be considered "filed" under the Securities Exchange Act. The report includes forward-looking statements regarding the company's expectations and projections, which are subject to various risks and uncertainties that could lead to actual results differing from those anticipated. Ensysce cautions against undue reliance on these statements, noting that updates will only be made as required by law. The filing was signed by Dr. Lynn Kirkpatrick, the President and CEO, indicating formal acknowledgment of the report's contents. Further details on the financial performance and specific figures are included in the attached press release.